<b>A:</b> Short axis high resolution, high field cardiac MRI of a FXIII^−/− mouse 2 days after coronary ligation.

<div><p>Arrows: intrathoracic hematoma adjacent to experimental anterolateral infarction.</p> <p> <b>B:</b> Autopsy confirms a blood clot (asterisk) originating from myocardial rupture at the border zone (arrow) of the myocardial infarct.</p> <p> <b>C:</b> Histology of 1A shows rupture channel (arrows), filled with blood.</p> <p> <b>D:</b> In patients with ruptured MI, FXIII levels were significantly reduced (*p<0.01).</p> <p> <b>E:</b> Color Doppler echo of patient with new ventricular septum defect 7 days after myocardial infarction (arrow).</p> <p> <b>F:</b> MRI after VSD repair with patch (arrows).</p> <p> <b>G–I:</b> Explantation site of saphenous veins for CABG surgery displays delayed healing.</p> <p> <b>J:</b> 73 days after initial surgery, 3 revisions and 2 weeks after i.v. FXIII augmentation, the wound is closed.</p></div

Clinical history in the total cohort and according to stages of Fabry cardiomyopathy.

<p>Mean observation period of 51 ± 24 months.</p><p>* p<0.005 intermediate CM baseline vs. intermediate CM follow-up</p><p>† p<0.005 advanced CM baseline vs. advanced CM follow-up</p><p>CAD, coronary artery disease</p><p>CM, cardiomyopathy</p><p>LE, late enhancement</p><p>ACVB, aorto-coronary vein bypass</p><p>ICD, implanted cardioverter defibrillator.</p><p>Clinical history in the total cohort and according to stages of Fabry cardiomyopathy.</p

Scatter plot of annual progression rate of myocardial fibrosis versus the alterations in geometry.

<p>On the x-axis values of the sphericity index (SI, parameter for geometry) and on the y-axis the annual progression of late enhancement (LE, parameter for fibrosis) is displayed. The size of the red dots represents the systolic blood pressure (SBP) at baseline. The vertical line indicates the pathological value of the SI. Note the appearance of high SI in combination with elevated SBP and high progression rate. EDV; End-diastolic volume.</p

Baseline characteristics of study participants in the total sample and stages of Fabry cardiomyopathy.

<p>Data in parenthesis are % of total</p><p>ACR, Albumine-creatinine-ratio</p><p>CM, cardiomyopathy</p><p>GI, gastrointestinal</p><p>TIA, transient ischemic attack</p><p>SBP, systolic blood pressure</p><p>DBP, diastolic blood presssure</p><p>AT, angiotensin</p><p>ACE, angiotensin converting enzyme</p><p>GFR, glomerular filtration rate</p><p>NYHA, New York Heart assosiation</p><p>NT-proBNP, N-terminal of brain natriuretic peptide</p><p>Hb, haemoglobin.</p><p>Significance at level 0.05 is indicated by</p><p>* for early vs. intermediate stage</p><p>† for intermediate vs. severe stage</p><p>‡ for early vs. severe stage</p><p>Baseline characteristics of study participants in the total sample and stages of Fabry cardiomyopathy.</p

Typical cardiac magnetic resonance imaging (cMRI) (A) and echocardiography (B) of patients with normal sphericity index (SI; right row) and elevated SI (left row).

<p>Note the pathological late enhancement (LE; white arrow) in the cMRI and the more spherical shape of the LV in the left row. SI; sphericity index, EDV; end-diastolic volume.</p

Overview of presumed factors and their interrelation influencing the progression of Fabry cardiomyopathy.

<p>BNP, Brain-natriuretic peptide; EDV, End-diastolic volume; GB3, globotriaosylceramide; LA, Left atrium; LV, Left ventricle.</p

ROC curves of different echocardiographic parameters to identify patients with fast progression of late enhancement (LE).

<p>Parameters in the legend are ordered by the AUC. EDV, End-diastolic volume; EF, Ejection fraction; FS, Fractional shortening; LA, Left atrial diameter; SBP, Systolic blood pressure; SI, Sphericity index.</p

Multivariate logistic regression analysis for correlation with rapid progression of late enhancement.

<p>SI, sphericity index</p><p>SBP, systolic blood pressure</p><p>LA, left atrial diameter</p><p>IVST, interventricular septal thickness</p><p>EF, ejection fraction</p><p>EDV, end-diastolic volume</p><p>FS, fractional shortening</p><p>NT-proBNP, n-terminal propeptide of brain natriuretic peptide</p><p>OR, odds ratio</p><p>CI, confidence interval</p><p>AUC, area under the curve</p><p>* p-value <0.05 for ROC-analysis.</p><p>Multivariate logistic regression analysis for correlation with rapid progression of late enhancement.</p

Updated (2015) risk charts for estimation of absolute 10-year risk (%) of fatal CVD in Germany based on the SCORE-Deutschland risk charts (tables with total cholesterol/HDL cholesterol ratio).

<p>Updated (2015) risk charts for estimation of absolute 10-year risk (%) of fatal CVD in Germany based on the SCORE-Deutschland risk charts (tables with total cholesterol/HDL cholesterol ratio).</p

Updated (2015) risk charts for estimation of absolute 10-year risk (%) of fatal CVD in Germany based on the SCORE-Deutschland risk charts (tables with total cholesterol).

<p>Updated (2015) risk charts for estimation of absolute 10-year risk (%) of fatal CVD in Germany based on the SCORE-Deutschland risk charts (tables with total cholesterol).</p